title: Current management of peripheral T-cell lymphomas.
abstract: Peripheral T-cell lymphomas (PTCLs) are an uncommon group of lymphoproliferative disorders accounting for approximately 10-15 % of all non-Hodgkin lymphomas (NHL) in Western countries. Although PTCLs are associated with poor prognosis, outcomes vary with disease subtype. The standard of care has been anthracycline-based induction combination chemotherapy, however, with the exception of low-risk ALK-positive anaplastic large cell lymphoma, relapse rates are high. Therefore, consolidation with autologous stem cell transplantation is usually recommended for patients deemed candidates, and with aggressive subtypes. In recent years, a number of novel agents including pralatrexate, histone deacetylase inhibitors, immunotoxins, proteasome inhibitors, aurora kinase inhibitors and the CD30 antibody-drug conjugate brentuximab vedotin, have shown promise in the treatment of PTCLs. Studies are underway to explore the activity of these newer agents used in the frontline setting.
authors: Thomas Jefferson University, 834, Chestnut Street, Suite 320, Philadelphia, PA, 19107, USA.
authors: M
authors: M
authors: Gooptu
authors: R
authors: R
authors: Rhoades
authors: B
authors: B
authors: Pro
mesh_terms: D000630:Aminopterin / Q000031:analogs & derivatives / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000079963:Brentuximab Vedotin; D004167:Diphtheria Toxin / Q000627:therapeutic use; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D016411:Lymphoma, T-Cell, Peripheral / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D058990:Molecular Targeted Therapy; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D033581:Stem Cell Transplantation
chemical_list: C418863:10-propargyl-10-deazaaminopterin; D000970:Antineoplastic Agents; D004167:Diphtheria Toxin; D056572:Histone Deacetylase Inhibitors; D018796:Immunoconjugates; D007376:Interleukin-2; D047428:Protein Kinase Inhibitors; D011993:Recombinant Fusion Proteins; C078456:denileukin diftitox; D000079963:Brentuximab Vedotin; D000630:Aminopterin